On this page
Cromolyn Sodium
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Cromolyn Sodium | 40 mg/mL | 831109 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Decreased Histamine Release [PE] | PE | All 16 members |
| Mast Cell Stabilizer [EPC] | EPC | All 16 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 075282-001 | CROMOLYN SODIUM | SOLUTION/DROPS | CROMOLYN SODIUM | Prescription | AT | RS |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 5 | Manufacturing (CMC) | Approved | December 23, 2002 | — |
| Supplement | 4 | Manufacturing (CMC) | Approved | October 1, 2002 | — |
| Supplement | 3 | Manufacturing (CMC) | Approved | March 28, 2002 | — |
| Supplement | 2 | Manufacturing (CMC) | Approved | April 7, 2000 | — |
| Supplement | 1 | Manufacturing (CMC) | Approved | October 7, 1999 | — |
| Original application | 1 | Approved | June 16, 1999 | — |
Review documents
- 0 · Original application · June 16, 1999
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260401). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Cromolyn Sodium Ophthalmic Solution USP, 4% is indicated in the treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION The dose is 1 or 2 drops in each eye 4 to 6 times a day at regular intervals. One drop contains approximately 1.6 mg cromolyn sodium. Patients should be advised that the effect of cromolyn sodium ophthalmic solution therapy is dependent upon its administration at regular intervals, as directed. Symptomatic response to therapy (decreased itching, tearing, redness, and discharge) is usually evident within a few days, but longer treatment for up to six weeks is sometimes required. Once symptomatic improvement has been established, therapy should be continued for as long as needed to sustain improvement. If required, corticosteroids may be used concomitantly with Cromolyn Sodium Ophthalmic Solution USP, 4%.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Cromolyn Sodium Ophthalmic Solution USP, 4% is contraindicated in those patients who have shown hypersensitivity to cromolyn sodium or to any of the other ingredients.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The most frequently reported adverse reaction attributed to the use of cromolyn sodium ophthalmic solution, on the basis of reoccurrence following readministration, is transient ocular stinging or burning upon instillation. The following adverse reactions have been reported as infrequent events. It is unclear whether they are attributable to the drug: Conjunctival injection; watery eyes; itchy eyes; dryness around the eye; puffy eyes; eye irritation; and styes. Immediate hypersensitivity reactions have been reported rarely and include dyspnea, edema and rash.
Description
openFDA Drug LabelingDESCRIPTION Cromolyn Sodium Ophthalmic Solution USP, 4% is a clear, colorless, sterile solution intended for topical ophthalmic use. Cromolyn sodium is represented by the following structural formula: Chemical Name: Disodium 5-5'-[(2-hydroxytrimethylene)dioxy]bis[4-oxo-4H-1-benzopyran-2-carboxylate] Pharmacologic Category: Mast cell stabilizer. EACH mL CONTAINS: Active: cromolyn sodium 40 mg (4%); Preservative: benzalkonium chloride 0.01%. Inactives: edetate disodium 0.1% and purified water. Hydrochloric acid and/or sodium hydroxide may be added to adjust pH (4.0-7.0). chemicalstructure
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Cromolyn Sodium Ophthalmic Solution USP, 4% is supplied in a white, opaque, plastic ophthalmic dispenser in the following sizes: 10 mL NDC 71205-230-10 Storage: Store between 15° - 30°C (59°- 86°F). Protect from light-store in original carton. Keep tightly closed and out of the reach of children. Rx Only
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: CROMOLYN SODIUM. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 50090-1202-0 | 50090-1202 | A-S Medication Solutions | 10 mL in 1 BOTTLE, PLASTIC (50090-1202-0) | November 28, 2014 |
| 68788-8490-1 | 68788-8490 | Preferred Pharmaceuticals Inc. | 10 mL in 1 BOTTLE, PLASTIC (68788-8490-1) | July 21, 2023 |
| 71205-230-10 | 71205-230 | Proficient Rx LP | 10 mL in 1 BOTTLE, PLASTIC (71205-230-10) | March 1, 2019 |
| 61314-237-10 | 61314-237 | Sandoz Inc | 1 BOTTLE, PLASTIC in 1 CARTON (61314-237-10) / 10 mL in 1 BOTTLE, PLASTIC | June 29, 1999 |
| 50090-1202 | 50090-1202 | A-S Medication Solutions | — | June 29, 1999 |
| 68788-8490 | 68788-8490 | Preferred Pharmaceuticals Inc. | — | July 21, 2023 |
| 71205-230 | 71205-230 | Proficient Rx LP | — | June 29, 1999 |
| 61314-237 | 61314-237 | Sandoz Inc | — | June 29, 1999 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.